AAPL 250.9362 1.1636% MSFT 439.85 0.5624% NVDA 132.26 2.5987% GOOGL 190.36 1.0403% GOOG 191.585 0.7547% AMZN 224.7026 1.8967% META 605.1 1.3245% AVGO 221.57 -0.9167% TSLA 434.8 -1.211% TSM 195.3 -0.133% LLY 758.87 -0.7637% V 315.9 1.9756% JPM 234.325 1.7168% UNH 493.79 -1.1867% NVO 103.7 -2.1329% WMT 93.89 0.3634% LVMUY 130.52 0.7721% XOM 105.67 -0.7048% LVMHF 649.5 0.6649% MA 526.755 1.3068%
Last update at 2024-12-19T18:55:00Z
7 F-Rated Stocks To Sell in July
Mon 08 Jul 24, 12:00 AM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -110.21800M | -92.28700M | -50.46300M | -28.61800M | -26.08900M |
| Minority interest | - | - | - | - | - |
| Net income | -115.00400M | -92.21200M | -50.38800M | -28.38200M | -26.08900M |
| Selling general administrative | 30.21M | 23.47M | 14.35M | 10.64M | 8.76M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | -112.09100M | -92.31200M | -50.51100M | -28.82800M | -26.32200M |
| Reconciled depreciation | 1.25M | 0.05M | 0.03M | 0.03M | 0.05M |
| Ebit | -113.34400M | -92.36200M | -50.53800M | -28.85400M | -26.37600M |
| Ebitda | -112.09100M | -92.31200M | -50.51100M | -28.82800M | -26.32200M |
| Depreciation and amortization | 1.25M | 0.05M | 0.03M | 0.03M | 0.05M |
| Non operating income net other | - | 0.03M | 0.05M | 0.21M | 0.23M |
| Operating income | -112.09100M | -92.31200M | -50.51100M | -28.82800M | -26.32200M |
| Other operating expenses | 112.09M | 92.31M | 50.51M | 28.83M | 26.32M |
| Interest expense | -7.91200M | 0.05M | 0.00000M | 0.00000M | 0.00000M |
| Tax provision | - | - | - | - | - |
| Interest income | 1.87M | 0.03M | 0.05M | 0.21M | 0.23M |
| Net interest income | 1.87M | 0.03M | 0.05M | 0.21M | 0.23M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 4.79M | -0.07500M | -0.07500M | -0.23600M | 0.23M |
| Total revenue | 0.00000M | 0.00000M | 0.00000M | 0.00000M | 0.00000M |
| Total operating expenses | 112.09M | 92.31M | 50.51M | 28.83M | 26.32M |
| Cost of revenue | 112.09M | 92.31M | 50.51M | 28.83M | 26.32M |
| Total other income expense net | 1.87M | 0.03M | 0.05M | 0.21M | 0.23M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -110.21800M | -92.28700M | -50.46300M | -28.61800M | -26.08900M |
| Net income applicable to common shares | -116.87700M | -92.28700M | -52.17400M | -31.09200M | -29.35500M |
| Preferred stock and other adjustments | - | - | 1.26M | 2.47M | 3.27M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 154.46M | 225.69M | 240.90M | 98.18M | 14.56M |
| Intangible assets | 9.74M | - | 0.12M | 0.12M | 0.12M |
| Earning assets | - | - | - | - | - |
| Other current assets | 4.08M | 10.55M | 10.39M | 10.92M | 2.70M |
| Total liab | 48.93M | 18.51M | 22.18M | 10.54M | 5.14M |
| Total stockholder equity | 105.53M | 207.18M | 218.72M | 87.65M | 9.42M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 9.50M | 6.41M | 5.11M | 2.46M | 1.01M |
| Common stock | 0.06M | 0.08M | 0.50M | 0.21M | 0.00900M |
| Capital stock | 0.06M | 0.08M | 0.50M | 0.21M | 0.00900M |
| Retained earnings | -600.65800M | -470.03800M | -359.82000M | -267.53300M | -217.07000M |
| Other liab | - | - | 22.18M | - | 5.14M |
| Good will | 0.96M | - | - | - | - |
| Other assets | - | 0.38M | 51.85M | 1.50M | 0.10M |
| Cash | 24.95M | 120.23M | 178.66M | 77.07M | 11.25M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 18.88M | 18.18M | 21.72M | 9.82M | 5.13M |
| Current deferred revenue | 2.98M | 3.27M | 2.83M | 2.17M | 0.70M |
| Net debt | -15.13500M | -119.46900M | -177.70400M | -75.75700M | -10.89100M |
| Short term debt | 2.62M | 0.43M | 0.49M | 0.59M | 0.35M |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 9.81M | 0.76M | 0.96M | 1.31M | 0.36M |
| Other stockholder equity | 706.36M | 677.31M | 578.13M | 355.04M | 226.52M |
| Property plant equipment | - | 94.53M | 51.47M | 9.83M | 0.03M |
| Total current assets | 47.77M | 130.78M | 189.05M | 87.99M | 13.95M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | 207.18M | 218.72M | 87.53M | 9.30M |
| Short term investments | - | - | - | - | - |
| Net receivables | 4.59M | 8.04M | 7.73M | 7.63M | 1.01M |
| Long term debt | 6.56M | - | - | - | - |
| Inventory | 14.15M | -8.04300M | -7.72600M | -7.62700M | -1.01100M |
| Accounts payable | 3.78M | 8.07M | 13.28M | 4.60M | 3.07M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -0.23200M | -0.16700M | -0.09200M | -0.06200M | -0.04600M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | 0.50M | 0.21M | 0.00900M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | -359.82000M | -267.53300M | -217.07000M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | -9.51400M | 0.38M | 0.26M | 0.24M | 0.10M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 106.69M | 94.91M | 51.85M | 10.19M | 0.61M |
| Capital lease obligations | 0.90M | 0.76M | 0.96M | 1.31M | 0.36M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -48.14700M | -35.30700M | -8.56400M | -0.01700M | -0.00600M |
| Change to liabilities | -1.04500M | 3.53M | 1.53M | 2.12M | 0.52M |
| Total cashflows from investing activities | -48.14700M | -35.30700M | -8.56400M | -0.01700M | -0.00600M |
| Net borrowings | - | - | - | - | - |
| Total cash from financing activities | 87.84M | 212.49M | 123.11M | 12.92M | 23.54M |
| Change to operating activities | 1.04M | 2.25M | -3.89400M | -1.21100M | 0.33M |
| Net income | -110.21800M | -92.28700M | -50.46300M | -28.61800M | -26.08900M |
| Change in cash | -58.43000M | 101.59M | 65.96M | -13.78500M | -0.45100M |
| Begin period cash flow | 178.90M | 77.31M | 11.35M | 25.13M | 25.59M |
| End period cash flow | 120.47M | 178.90M | 77.31M | 11.35M | 25.13M |
| Total cash from operating activities | -98.05300M | -75.55700M | -48.56600M | -26.68300M | -23.97100M |
| Issuance of capital stock | 135.05M | 212.39M | 113.21M | 12.85M | 23.54M |
| Depreciation | 1.25M | 0.05M | 0.03M | 0.03M | 0.05M |
| Other cashflows from investing activities | - | - | - | - | - |
| Dividends paid | -6.65900M | - | -0.45100M | -2.47400M | 3.27M |
| Change to inventory | - | - | - | - | - |
| Change to account receivables | - | - | - | - | - |
| Sale purchase of stock | -47.25000M | 3.00M | 1.36M | 12.92M | 23.54M |
| Other cashflows from financing activities | 47.29M | -2.90200M | 14.50M | 9.52M | 14.09M |
| Change to netincome | 10.91M | 10.90M | 4.24M | 1.46M | 1.63M |
| Capital expenditures | 48.15M | 35.31M | 8.56M | 0.02M | 0.00600M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | 3.51M | -5.44800M | -1.67300M | -0.07900M |
| Exchange rate changes | - | - | - | - | -0.01300M |
| Cash and cash equivalents changes | - | 101.62M | 65.97M | -13.78100M | -0.45100M |
| Change in working capital | -0.00200M | 5.78M | -2.36600M | 0.45M | 0.44M |
| Stock based compensation | 10.91M | 7.90M | 2.88M | 1.46M | 1.63M |
| Other non cash items | - | 3.00M | 1.36M | 15.04M | 1.35M |
| Free cash flow | -146.20000M | -110.86400M | -57.13000M | -26.70000M | -23.97700M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| TNXP Tonix Pharmaceuticals Holding Corp |
0.31 85.03% | 0.68 | - | - | 2.00 | 0.15 | 0.04 | -0.0028 |
| NVO Novo Nordisk A/S |
-2.26 2.13% | 103.70 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
-1.68 1.57% | 105.12 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-55.6951 12.45% | 391.80 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
-4.445 0.62% | 710.17 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. The company was founded in 2007 and is headquartered in Chatham, New Jersey.
26 Main Street, Chatham, NJ, United States, 07928
| Name | Title | Year Born |
|---|---|---|
| Dr. Seth Lederman M.D. | Co-Founder, Pres, CEO & Chairman | 1958 |
| Mr. Bradley Saenger CPA, CPA | CFO & Treasurer | 1974 |
| Dr. Gregory M. Sullivan M.D. | Chief Medical Officer & Sec. | 1966 |
| Mrs. Jessica Edgar Morris | Chief Operating Officer | NA |
| Dr. Herbert W. Harris M.D., Ph.D. | Exec. VP of Translational Medicine | NA |
| Dr. Bruce L. Daugherty M.B.A., Ph.D. | Exec. VP of Research | 1958 |
| Ms. Siobhan Fogarty B.Sc., M.Sc. | Exec. VP of Product Devel. | NA |
| Dr. Darryl Rideout Ph.D. | Exec. VP of Experimental Chemistry | NA |
| Dr. Sina Bavari Ph.D. | Exec. VP of Infectious Disease R&D | NA |
| Dr. Daniel J. Clauw M.D. | Consultant | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US 
AU
UK
CA
NZ
Please wait processing your request...